

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64082

Title: Low symptomatic COVID-19 in the elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report

Reviewer's code: 03468046

Position: Peer Reviewer

Academic degree: DSc, PhD

Professional title: Instructor

Reviewer's Country/Territory: United States

Author's Country/Territory: Poland

Manuscript submission date: 2021-02-08

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-04 02:03

Reviewer performed review: 2021-03-07 18:30

Review time: 3 Days and 16 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Language quality	<input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection
Conclusion	<input type="radio"/> Accept (High priority) <input checked="" type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input type="radio"/> Major revision <input type="radio"/> Rejection
Re-review	<input type="radio"/> Yes <input checked="" type="radio"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="radio"/> Anonymous <input type="radio"/> Onymous Conflicts-of-Interest: <input type="radio"/> Yes <input checked="" type="radio"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Well written manuscript. No further improvement required.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64082

Title: Low symptomatic COVID-19 in the elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report

Reviewer's code: 03071047

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: Poland

Manuscript submission date: 2021-02-08

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-03-05 17:26

Reviewer performed review: 2021-03-21 18:14

Review time: 16 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In this paper authors describe a good outcome found in a patient affected of follicular lymphoma treated with anti CD20 rituximab. This is an interesting outcome based in the poor association anti-CD20 and SARS CoV 2 published Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature Br J Haematol2020 Jul;190(2):185-188 Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 J Neurol 2020 May;267(5):1567-1569 Although the description is clear, there are some issues that should be clarified: 1) Were the authors aware the SARS CoV 2 status in the patient prior to start the chemotherapy cycles? 2) What test were performed by the diagnosis of SARS CoV 2 by nasopharyngeal swab? Antigenic test? PCR test? Could it have been a false positive result in the test ? How they been able to rule it out? 3) Based in this case, would you recommend maintaining a possible treatment with rituximab in a cancer patient affected by Covid 19? In the literature it is advised to interrupt 4) Authors should discuss how can affect rituximab treatment by the success of possible future vaccine in the patient.